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Atherosclerosis and its thrombotic complications are the major cause of morbidity and mortality in the industrialized countries. Despite
advances in our understanding of the pathophysiology, pathogenesis, and new treatment modalities, the absence of an adequate non-invasive
imaging tool for early detection limits both the prevention and treatment of patients with various degrees and anatomical localizations of
atherothrombotic disease. An ideal clinical imaging modality for atherosclerotic vascular disease should be safe, inexpensive, non-invasive
or minimally invasive, accurate, and reproducible, and the results should correlate with the extent of atherosclerotic disease and have
high predictive values for future clinical events. High-resolution magnetic resonance imaging (MRI) has emerged as the most promising tech-
nique for studying atherothrombotic disease in humans in vivo. Most importantly, MRI allows for the characterization of plaque composition,
i.e. the discrimination of lipid core, fibrosis, calcification, and intraplaque haemorrhage deposits. Magnetic resonance imaging also allows for
the detection of arterial thrombi and in defining thrombus age. Magnetic resonance imaging has been used to monitor plaque progression
and regression in several animal models of atherosclerosis and in humans. Emerging MRI techniques capable of imaging biological processes,
including inflammation, neovascularization, and mechanical forces, may aid in advancing our understanding of the atherothrombotic disease.
Advances in diagnosis do prosper provided they march hand-in-hand with advances in treatment. We stand at the threshold of accurate non-
invasive assessment of atherosclerosis. Thus, MRI opens new strategies ranging from screening of high-risk patients for early detection and
treatment as well as monitoring of the target lesions for pharmacological intervention. Identification of subclinical atherosclerosis and early
treatment initiation has the potential to surpass conventional risk factor assessment and management in terms of overall impact on cardi-
ovascular morbidity and mortality. Such strategy is currently under clinical investigation.
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Introduction
Atherothrombosis is a systemic arterial disease mainly involving the
intima of large- and medium-sized systemic arteries, most commonly
the carotid, aorta, coronary, and peripheral arteries. The main com-
ponents of the atherothrombotic plaques are: (i) connective tissue
extracellular matrix, including collagen, proteoglycans, fibronectin,
and elastic fibres; (ii) crystalline cholesterol, cholesteryl esters, and
phospholipids; (iii) cells such as monocyte-derived macrophages,
T-lymphocytes, and smooth muscle cells, and eventually (iv) throm-
botic material with platelets and fibrin. Varying proportions of these
components occur in different plaques, thus giving rise to a hetero-
geneity of lesions.1 –3 These components mainly affect the intima
within the subendothelial space, but secondary changes also occur
in the media and adventitia,4 particularly the growth of vasa
vasorum.5 Exemplifying the heterogeneity of lesions, disruption-
prone plaques in the coronary arteries, the so-called high-risk or
‘vulnerable plaques’, tend to have a thin fibrous cap (cap thickness
,65 mm), a large lipid core (.40% of the total lesion area), and a
high degree of inflammation.1,6,7 In contrast, carotid artery plaques
prone to rupture are severely stenotic and predominantly fibrotic.8
Since the composition of the ‘high-risk plaques’ varies depending on
their anatomical site, with striking heterogeneity even within the
same individual, reliable non-invasive imaging modalities able to
detect and characterize atherothrombotic disease in its various
stages and their different anatomical regions are clinically desirable.9
Such imaging modalities would improve our understanding of the
pathophysiological mechanisms underlying the atherothrombotic
processes and allow for better risk stratification of the overall
‘burden’ of disease. Additionally, such tools may permit optimal
tailoring of treatment and allow direct monitoring of the vascular
response.10
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Techniques such as magnetic resonance imaging (MRI) are
critical for the development of novel therapeutics as they allow
for precise monitoring of the treatment effects over time.
Advances in diagnosis therefore prosper when they march
hand-in-hand with advances in treatment. Today, we stand at the
threshold of accurate non-invasive assessment of atherosclerosis.
Identification of subclinical atherosclerosis and early treatment
initiation has the potential to surpass conventional risk factor
assessment and management in terms of overall impact on cardio-
vascular morbidity and mortality. Such a strategy is currently under
clinical investigation in the High-Risk Plaque Bioimaging Study in
which novel approaches are tested in a typical health-plan popu-
lation.11 This study has recruited 6000 active subjects and 1300
controls, of which a large proportion underwent non-invasive
imaging [including ultrasound, computed tomography (CT), posi-
tron emission tomography (PET) and MRI] and are being followed
for clinical events and resource use up to 3 years.
The aim of the present article is to provide an overview of the
feasibility and validation data, as well as the research and clinical
application of MRI to study atherosclerotic plaques.
Imaging of atherosclerosis
The assessment of atherosclerotic plaque burden by non-invasive
imaging techniques should allow for early detection of the disease
and in vivo identification of high-risk plaques.10,12,13 Several invasive
and non-invasive imaging techniques are available with which athero-
sclerotic disease can be assessed.13 The angiogram, using X-ray
technology as does CT, or MR, all provide excellent spatial resol-
ution allowing to detect the presence of stenosis, the degree of
luminal narrowing, and/or information of the luminal surface of pro-
truding atherothrombotic disease. The use of non-invasive angiogra-
phy techniques, with intravenous injection of a contrast agent, has
become a routine clinical practice at many centres to outline the
degree of stenosis of the carotid, renal, and peripheral arteries,
and the aorta. Importantly, however, as plaques may be displaced
outward, due to the so-called positive remodelling, the luminal diam-
eter may appear normal despite significant disease.14 Today, the goal
of visualizing and characterizing the diseased arterial wall in patients
has become a reality with the use of several imaging techniques. Inva-
sive techniques such as intravascular ultrasound (IVUS) and IVUS-
derived techniques (such as palpography, elastography, and virtual
histology) can assess arterial remodelling, plaque characteristics of
coronary arteries, and optical coherence tomography allows ‘near-
histological’ resolution of plaque surface, providing crucial morpho-
logical information, and is currently standard in clinical research.
Such techniques, once adequately validated, might potentially help
to define the vulnerability of coronary atherosclerotic plaques.
High-resolution MRI has emerged as the leading non-invasive
in vivo imaging modality for atherosclerotic plaque characterization.
Magnetic resonance imaging does not involve ionizing radiation
and can provide high-resolution images of multiple vascular terri-
tories. The MR image is based on the radiofrequency signal, typically
from water protons, following administration of a radiofrequency
pulse, while the subject is placed in a strong magnetic field. The
emitted signal varies according to the water concentration and the
relaxation times (T1 and T2). Using combined analysis of different
tissue signal intensities generated by the application of T1-weigted
(T1W), T2-weigted (T2W), and proton-density-weighted (PDW)
images, it has been possible to determine both plaque anatomy
and composition.15 Thus, MRI differentiates plaque components on
the basis of biophysical and biochemical parameters such as chemical
composition, water content, physical state, molecular motion, or dif-
fusion. Magnetic resonance imaging provides imaging without ionizing
radiation and can be repeated sequentially over time.
Atherosclerotic plaque characterization by MRI is based on the
signal intensities and morphological appearance of the plaque on
multiple different contrast weighting. The key advantage of MRI
is the opportunity to acquire and combine multicontrast images,
both bright blood (such as time-of-flight, TOF) and black blood
(such as T1W, T2W, and PDW with blood-flow suppression) to
distinguish tissue composition within the atherosclerotic vessel
wall.9,16 High-resolution contrast weighting MRI has been used
for in vivo assessment of atherosclerotic plaques in the human
carotids (Figure 1),9,16– 18 aortic,9,19 peripheral,20,21 and coronary
arterial disease.22 –24
Feasibility and validation studies
for plaque imaging using magnetic
resonance imaging
The assessment of both the anatomy and composition of athero-
sclerotic plaques by MRI has been extensively validated in exper-
imental models and in humans. Validation studies were initially
performed in experimental models of atherosclerosis such as in
cholesterol-fed rabbits25,26 and pigs using clinically available MRI
scanners and in mice27 using high-field-strength MRI scanners.
Worthley et al. were the first validating the MR technique for cor-
onary plaque imaging ex vivo28 and in vivo22 in a clinical MRI scanner
using a porcine model. In humans, validation was initially performed
ex vivo using histological specimens29,30 and subsequently in vivo in
patients scheduled for carotid endarterectomy16,18,31– 35 or before
surgical grafting of abdominal aortic aneurysm,36 in which in vivo
MR images were compared with histology.
Measurement of plaque size
Yuan and his group did extensive validation work on the carotid
plaques. They were the first assessing the accuracy of vessel wall
measurement using carotid high-resolution MRI in patients sched-
uled for endarterectomy.18 The carotid lesions were excised
en bloc and scanned again using similar imaging parameters. The
paired in vivo and ex vivo measurements strongly agreed on the
mean difference (in vivo minus ex vivo) in vessel wall area (VWA).
Intra and inter-observer variability was small, with intraclass corre-
lation coefficients ranging from 0.90 to 0.98. They concluded that
MRI is highly accurate for in vivo measurement of VWA in athero-
sclerotic carotid lesions. This study showed for the first time that
this imaging technique has potential application in monitoring
lesion size in studies examining plaque progression and regression.
We reported similar in vivo reproducibility data for VWA measure-
ment by repeated MRI of the carotid arteries and thoracic aorta.37
The image-specific error (standard deviation between matched
image) was 6 mm2 for aortic and 2 mm2 for carotid images.
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By averaging the values of five-contiguous images, the error was
reduced to 4.5 mm2 for aortic and 1.5 mm2 for carotid images,
corresponding to an error of 2.6% for aortic and 3.5% for
carotid plaques. On the basis of these reproducibility data,
changes in plaque size of .5% for aortic and .7% for carotid
lesions are likely to be accurately measured by MRI.
Fayad et al.19 assessed the atherosclerosis of the thoracic aorta
by MRI and transoesophageal echocardiography (TEE)38 and
showed a strong correlation for plaque composition and mean
maximum plaque thickness. Overall aortic plaque extent as
assessed by TEE and MR was also statistically significant.
Assessment of plaque composition
In vivo assessment of plaque composition was initially performed
in small animals such as rabbit25,26 and mice.27 Images were
acquired in vivo and then correlated with the fine structure of
the atherosclerotic lesions, including the fibrous cap, necrotic
core, and lesion fissures, as verified by gross examination, dissec-
tion microscopy, and histology. In genetically engineered mice,
excellent agreement between high-field MR and histopathology
in grading of lesion shape and type was demonstrated.27
Similar results have been described in the rabbit model using
clinical MR scans.25 Magnetic resonance imaging was performed
in a 1.5 T system 9 months after induction of aortic athero-
sclerotic lesions, and the images were compared with matched
histopathological sections.25 A significant correlation was
observed for mean wall thickness (r ¼ 0.87), VWA (r ¼ 0.85),
and for plaque composition for the analysis of lipid rich
(low signal on T2W, r ¼ 0.81) and fibrous (high signal on
T2W, r ¼ 0.86) areas between MRI and histopathology. These
studies indicated that serial analysis of therapeutic strategies on
atherosclerotic plaque stabilization is feasible. Non-invasive
high-resolution MRI has therefore demonstrated the potential
Figure 1 Magnetic resonance imaging of the carotid artery in a patient with arterial hypertension. The angiography with intravenous injection
of gadolinium demonstrates a subtotal stenosis of the left carotid artery followed by a 3608 loop due to the elongation of the artery. High-
resolution magnetic resonance imaging allows visualization of the extension of the atherosclerotic plaque and anatomical distribution in relation
to the surrounding structures.9
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to be applied in vivo as has been demonstrated by ex vivo exper-
iments in the animal model.
In the validation of novel imaging techniques, it is essential to be
able to bridge from pre-clinical models to humans. This was the
case for MRI: in fact, several investigators used endarterectomy
specimens to validate this technique in human first using ex vivo
and then in vivo study design by imaging the patients in vivo
before endarterectomy. Soila et al.39 and Maynor et al.40 have
demonstrated that lipid components of atherosclerotic plaque
could be distinguished with MRI. Toussaint et al.29– 31,41 showed
that MRI was useful for the identification of fibrous cap character-
istics. They found that calcification, fibrous intimal tissue, and
intraplaque haemorrhage could be identified based on T2
measurements of carotid plaques in vivo.29– 31,41
Although these images may still appear difficult to interpret to the
reader who is not an expert, improvement in the technology is rapidly
occurring and may one day be seen as the key technology to learn
more about the mechanisms leading to atherosclerotic progression.
Assessment of atherosclerotic
carotid artery plaques
The carotid arteries’ superficial location (Figure 1) and relative
absence of motion make them more suitable for MRI studies
than do vessels such as the aorta or particularly the coronary
arteries. Some of the carotid plaque MRI studies attempted both
imaging and characterization of normal and pathological arterial
walls,31 the quantification of plaque size,18 and the detection of
fibrous cap integrity.42 Magnetic resonance angiography can be
combined with multicontrast, high-resolution black-blood
spin-echo MRI sequences. Magnetic resonance angiography pro-
vides information on the severity of stenotic lesions and their
spatial distribution, whereas the high-resolution black-blood
sequences allow the characterization of plaque composition
(Figure 2). This strategy may potentially allow patient risk stratifica-
tion and selection of the adequate treatment modality.9
A strong association between fibrous cap thinning or rupture, as
determined by MRI vessel wall TOF imaging, and the history of
recent TIA or stroke was demonstrated (Figure 3).17 The associ-
ation between the presence of carotid intraplaque haemorrhage
and neurological events was first described in endarterectomy
specimens.43 Intraplaque haemorrhage and fibrous cap disruption
have been then documented in vivo by MRI in patients with symp-
tomatic carotid stenosis.17,44,45 High-intensity signals can be highly
suggestive of complicated plaque by using specific magnetic reson-
ance sequences designed for direct thrombus imaging (Figure 4).
The prevalence of high signal was significantly greater in the
patients’ symptom-related ipsilateral vessels compared with the
contralateral, asymptomatic side (60 vs. 36%, x2 P, 0.001),
Figure 2 Magnetic resonance imaging examination of carotid atherosclerotic plaque in a patient with symptomatic carotid disease. An echo
sequence is used to localize the carotid bifurcation (upper panel, left) and time-of-flight (TOF) sequence allows the definition of the stenosis
without needing contrast injection (upper panel, right). Multisequence high-resolution magnetic resonance demonstrates the presence of a
severely stenotic plaque with a large lipid core (yellow arrow in T2W image) (published with the permission of Prof. Dr A. Gallino and
Dr R. Wyttenbach, Bellinzona, Switzerland).
R. Corti and V. Fuster1712
Figure 3 Magnetic resonance sequences normally used to perform angiography without the need of contrast agent (time-of-flight) allow the
in vivo visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque. Gross and histological sections (lower left
panel) showing the area of cap rupture (arrow 1) covering the recent intraplaque haemorrhage (arrow 2) and next to a region where
fibrous cap is thick (arrow 3) (modified with permission from Yuan et al.17 and Hatsukami et al.42).
Figure 4 Specific designed sequences for the visualization of thrombi allow detection of intraplaque haemorrhage (arrow) in stroke patients
(modified with permission from Moody et al.76).
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particularly for vessels of only moderate stenosis.46 The prevalence
of AHA type VI carotid lesions (presenting luminal surface defect,
haemorrhage/thrombus, or calcified nodules) has been studied in
vivo using MRI in patients (n ¼ 192) with a different degree of
carotid stenosis.47 Lipid-rich necrotic core increased substantially
with a higher degree of stenosis. Significant negative correlation
between the minimum lumen area and complicated AHA type VI
plaques was found. In fact, 92% of all patients with high-degree ste-
nosis (80–99% luminal narrowing) had a lesion with lipid-rich
necrotic core. Furthermore, the complicated AHA type VI posi-
tively correlated with the maximum wall area.
Morerecently, using3 TMRI, it hasbeenshownthat intraplaquehaem-
orrhageand large lipid-richcoreare independentlyassociatedwith thinor
ruptured fibrous caps in patients with ≥50% carotid stenosis.48
Underhill et al.49 recently provided prospective evidence that
intraplaque haemorrhage could be a driving force behind luminal
obstruction and, therefore, could be a potential mechanistic expla-
nation for rapid plaque progression. Neovasculature, principally
arising from the vasa vasorum as a consequence of inflammation-
induced angiogenesis, has been implicated in the aetiology of
intraplaque haemorrhage. Indeed, the newly formed vessels
within plaques appear particularly prone to rupture. Thus, given
the impact of neovasculature on disease progression, the opportu-
nity to provide in vivo imaging of these structures to provide new
mechanistic insights is particularly appealing.50,51
In patients with acute stroke, high-resolution MRI has therefore
the potential of providing the essential information on the cause of
vessel obstruction, differentiating between thrombo-embolic
occlusion, plaque rupture, or dissection (Figure 5).
Assessment of aortic plaques
The principal challenges associated with MRI of the thoracic aorta
are obtaining sufficient sensitivity for submillimetre imaging and
exclusion of artifacts due to respiratory motion and pulsatile
changes due to the blood flow. These challenges have been met
using recent technical improvements such as increasing magnetic
field strength, dedicated sequences (such as double-inversion
preparation pulses to suppress the signal of flowing blood), and
navigator techniques to correct for respiratory motion.
Figure 5 Magnetic resonance angiography demonstrating a subtotal stenosis of the right internal carotid artery (arrow) in a patient with acute
stroke. High-resolution multicontrast imaging demonstrates a disrupted plaque with intraplaque haemorrhage as a cause of the subtotal
obstruction (middle panels). Details of the cross-sectional multicontrast magnetic resonance images (four-fold enlargement) are provided in
the right panels (published with the permission of Prof. Dr A. Gallino and Dr R. Wyttenbach, Bellinzona, Switzerland).
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Increased wall thickness of the ascending aorta was demon-
strated in patients with homozygous familial hypercholesterolaemia
(Figure 6).52 The use of contrast enhancement with gadolinium-
DTPA aids in the differentiation of plaque components in abdomi-
nal aortic aneurysm.36 In asymptomatic subjects followed in the
Framingham Heart Study (FHS), MRI was used to assess the
prevalence and extent of atherosclerotic disease. Plaque burden
significantly increased with age and was higher in the abdominal
aorta than in the thoracic aorta.53 It was also found that long-term
measures of risk factors and FHS coronary risk score are strongly
associated with asymptomatic aortic atherosclerosis as detected by
MR.54 Another study showed an association between the distri-
bution of aortic atherosclerosis and both the presence of cardio-
vascular risk factors and coronary artery disease in patients
referred for coronary angiography.55 It was also highlighted that
the thoracic and abdominal aorta might have different suscepti-
bilities to risk factors.
Wentzel et al.56 reported the association between plaque distri-
bution and size and average low shear stress locations. The data
support the role of local haemodynamic conditions in the develop-
ment of atherosclerotic lesions in descending thoracic aorta
(Figure 7).
Assessment of peripheral artery
plaques
High-resolution MR plaque imaging of the femoral and popliteal
artery and the response to balloon angioplasty have been recently
reported.20,21 Coulden et al.21 identified atherosclerotic lesions
with cross-sectional areas ranging from 49 to 76% of the potential
lumen area even in angiographically ‘normal’ vessel segments.
Following percutaneous transluminal angioplasty (PTA), plaque
fissuring and local dissection have been easily identified by MRI,
and serial changes in lumen diameter, blood flow, and lesion size
can be documented. Corti et al.20 showed that cross-sectional
high-resolution MRI performed 24 h after PTA at the level of the
arterial occlusion revealed severe disruption and splitting of the
atherosclerotic plaque, resulting in an irregular-shaped lumen
(Figure 8). Angiographic and MR images were clearly discrepant,
with angiography underestimating the residual lesion. This obser-
vation provided in vivo evidence of extensive plaque disruption
induced by balloon angioplasty and may explain mechanisms of
potential complications of this invasive treatment. More recently,
Wyttenbach et al.57 reported the effects of PTA and endovascular
brachytherapy on vascular remodelling of human femoropopliteal
artery by non-invasive MRI. Therefore, cross-sectional analysis by
MRI could be useful in follow-up to define plaque remodelling
and, perhaps, to identify prognostic factors for restenosis (e.g.
plaque splitting).
Assessment of coronary
atherosclerosis
Obviously, the ultimate goal would be non-invasive imaging of cor-
onary artery plaque. After preliminary studies in the pig model,22,28
high-resolution black-blood MRI of both normal and atherosclero-
tic human coronary arteries was performed. Fayad et al.23 were the
first to demonstrate the feasibility of coronary plaque imaging in
humans in vivo. Coronary MR plaque imaging was performed
during breath holding in order to minimize respiratory motion.
This technique was subsequently improved by Botnar et al.,58
allowing for high-resolution coronary plaque imaging during free
Figure 6 Magnetic resonance imaging high-resolution T2W oblique imaging of the aortic arch demonstrating an atherosclerotic plaque par-
ticularly evident in the posterior wall (arrow) extending in the left subclavian artery (A). (B) A protruding 4 mm thick plaque at the level of the
distal thoracic aorta.
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breathing. To alleviate the need for breath holding, the black-blood
fast-spin echo method has been combined with a real-time naviga-
tor for respiratory gating and real-time slice-position correc-
tion.58– 60 Near isotropic spatial-resolution black-blood imaging
may provide a quick way to image a long segment of the coronary
artery wall and may be useful for rapid coronary plaque burden
assessment.61 Further improvement in external coils, as well as
the use of contrast agents that enhance the different vessel wall
components, may improve MR characterization of the high-risk
plaque in the coronary arteries.
Multimodality and molecular
imaging
The combination of different modalities allows useful synergies
for non-invasive in vivo imaging. This approach was used to
investigate plaque neovascularization and inflammation in exper-
imental atherosclerosis in vivo by combining contrast-enhanced
MRI and PET at the level of the atherosclerotic aorta.62
Fusion technology to combine different imaging approaches
was also tested in humans at the level of the carotid arteries
(Figure 9).
Of particular interest is the development of novel molecular
enhancers that allow the targeted imaging of cells, molecules,
and biological processes.15 Such an approach most likely will
allow a more detailed characterization of the biological proper-
ties of atherosclerotic plaques, which up to now is not possible
in vivo. Molecular targets for fibrin, macrophages, and high-density
lipoprotein (HDL) have been tested at the pre-clinical level to
visualize thrombotic material, inflammation, or transport of
HDL metabolism within atherosclerotic plaques in vivo.63,64 The
ability to image the presence or biological activity of specific
molecules (‘molecular imaging’) in atherosclerotic plaques in
vivo is of considerable interest. Assessment of molecular infor-
mation in vivo requires high-affinity, target-specific contrast
agents, with marked signal amplification, and high-resolution
imaging modalities, such as magnetic resonance. Most of the
available paramagnetic magnetic MRI contrast agent constructs,
however, are not capable of delivering a large amount of gado-
linium ions to induce a large MRI signal. Moreover, some of
the MRI contrast agents may be too large to have free access
to biochemical epitopes within the vascular subendothelium of
atherosclerotic plaques. The role of specific enhancers deserves
therefore further investigation.
Magnetic resonance imaging
to monitor the effect of an
intervention on atherosclerotic
lesions
Advances in diagnosis prosper when they march hand-in-hand with
advances in treatment. We stand at the threshold of accurate non-
invasive assessment of atherosclerosis. Several investigators have
recently used serial non-invasive MRI to assess in vivo the effects
of interventional strategies (such as dietary interventions, systemic
medical therapy, or percutaneous balloon treatment) on animal
models of arteriosclerosis and in humans.
Figure 7 Velocity profiles at different levels of the descending aorta (left panel) can be measured by magnetic resonance imaging and used to
derive shear stress. The middle panel show the velocity spectral analysis for the different segment and the right panel indicates the related shear
stress condition as described by Wentzel et al.56
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Monitoring of interventions
in experimental arteriosclerosis
McConnell et al.65 studied the effects of dietary cholesterol-
lowering interventions in rabbits. Arteriosclerosis was induced by
a combination of aortic balloon injury and high-cholesterol diet
for 4 months. The animals were then assigned to low-cholesterol
vs. continued high-cholesterol diet for up to an additional 16
months. Aortic plaque progression was noted in rabbits maintained
on a high-cholesterol diet, whereas plaque regression occurred after
resuming a low-cholesterol diet. In Watanabe heritable hyperlipi-
daemic rabbits which lack the LDL receptor, Worthley et al.66 per-
formed serial MRI at baseline and 6 months after aortic balloon
denudation and reported that the increase in atherosclerotic
plaque burden over time was completely accounted for by positive
arterial remodelling. Corti et al.67 reported plaque regression and
features of plaque stabilization by a combination of statins and a
selective agonist of peroxisomal proliferator-activated receptor
gamma (PPARg-agonist) in the atherosclerotic rabbit. Viles-
Gonzalez et al.68 studied the effect of a novel antithrombotic
therapy by inhibition of the thromboxane A2 receptor on aortic
atherosclerotic lesion in rabbits. They reported regression of
advanced atherosclerotic plaques and the reduction in the
markers for macrophages, apoptotic cells, metalloproteinases, and
endothelin-1 and an increase in vascular smooth muscle cells,
suggesting that this thromboxane A2 receptor inhibitor may not
only halt the progression of atherosclerosis, but also transform
lesions towards a more stable phenotype. They concluded that
the possibility of combining antithrombotic and antiatherosclerotic
activity by means of the administration of thromboxane A2 receptor
inhibitors deserves further investigation in a clinical setting.
Figure 9 The positron emission tomography–magnetic resonance fusion images of the carotid arteries performed in a patient with acute
stroke demonstrate a ‘hot spot’ (yellow arrow) at the origin of the right internal carotid artery. This could potentially reflect the inflammation
(as detected by positron emission tomography) responsible for the rupture of the atherosclerotic plaque (published with the permission of
Prof. A. Gallino, Prof. L. Giovanella, and Dr L. Ceriani, Bellinzona, Switzerland).
Figure 8 Effect of percutaneous transluminal angioplasty on
severe femoral stenosis. Angiography (upper panel) and high-
resolution magnetic resonance imaging (lower panel) before
and after percutaneous transluminal angioplasty. SFA, superficial
femoral artery.
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In vivo monitoring of therapy with
magnetic resonance imaging in humans
Effects of lipid-lowering by statin
Corti et al.37 used in vivo MRI to quantify the effects of lipid-lowering
therapy by statins in asymptomatic previously untreated hypercho-
lesterolemic patients with carotid and aortic atherosclerosis. Ather-
osclerotic plaques were visualized and measured with MRI at
different time points in a longitudinal, uncontrolled study. Significant
regression of atherosclerotic lesions was observed. Importantly,
despite the early and expected lipid-lowering effect of the statins,
a minimum of 12 months was needed to observe significant
changes of the vessel wall in early atherosclerotic disease. In a
more recent study using a similar design in patients with coronary
artery disease (therefore expected to have more advanced
disease) significant regression was already seen at 6 months.38
Corti et al. observed a decrease in the VWA but no change in the
lumen area at 12 months. A longer follow-up showed a continued
reduction in the arterial wall area and even a small, but significant,
increase in the arterial lumen at 24 months (Figure 10).69 In the
same study population, Wentzel et al.56 showed that shear stress
does not seem to be the major predictor for plaque regression by
lipid-lowering interventions, suggesting that other mechanisms are
involved in the lipid-reversal mechanism.
Lima et al.38 measured atherosclerotic plaques in the thoracic
aorta by combined surface and transoesophageal MRI in 27 patients
(treated with simvastatin 20–80 mg daily) before and after 6 months
of therapy. They confirmed that plaque regression was strongly
associated with LDL cholesterol reduction. A post hoc analysis of
the study by Corti et al.71 revealed that the changes in vessel wall par-
ameters are more related to LDL cholesterol reduction rather than
the dose of statin. In fact, no difference in vascular effects was
detected between the randomized doses (simvastatin 20 vs.
80 mg). More interestingly, patients reaching mean on-treatment
LDL cholesterol ≤100 mg/dL showed larger decreases in plaque
size compared with patients who did not reach this goal.
In another study, 43 patients with moderate hypercholesterolae-
mia (LDL cholesterol between 100 and 250 mg/dL) and ,80%
carotid stenosis by duplex ultrasound were randomized to
receive either a low (5 mg) or high (40/80 mg) dose of rosuvasta-
tin. The significant reduction in LDL cholesterin levels has paral-
leled with a reduction in lipid-rich necrotic core size at 24
months. Interestingly, rosuvastatin was associated with a reduction
in lipid-rich necrotic core size, whereas the overall plaque burden
remained unchanged over the course of 2 years of treatment.
More recently, the ATHEROMA study demonstrated that
aggressive lipid lowering with atorvastatin 80 mg daily over a
3-month period was associated with a significant reduction in
plaque inflammation measured using ultrasmall superparamagnetic
iron oxide particles.70
Using the same study design, Yonemura et al.72 investigated the
effects of 20 vs. 5 mg atorvastatin on thoracic and abdominal aortic
plaques in 40 hypercholesterolaemic Japanese patients who were
randomized to receive either dose. They reported that 1-year
20 mg atorvastatin treatment induced regression of thoracic
aortic plaques with marked LDL cholesterol reduction, whereas
it only retarded plaque progression in the abdominal aorta. Poss-
ibly, thoracic and abdominal aortic plaques may have different sus-
ceptibilities to lipid lowering. In another remarkable study, Zhao
et al.73 examined carotid plaque composition quantitatively by
MRI in eight patients with combined hyperlipidaemia who had
been treated intensively with lovastatin, niacin, and colestipol for
10 years. An untreated, non-randomized control group was com-
posed of eight patients matched for age and baseline lipoproteins.
In the control group, the atherosclerotic lipid core comprised 17%
of carotid intima–media cross-sectional area. In the treated group,
only 1% of the cross-sectional area belonged to the lipid core (P ¼
0.01 for the comparison). Thus, the lipid core seemed to be almost
eliminated from the lesions by metabolic/pharmacological treat-
ment. The 8 treated patients were randomly chosen from a
larger group of 60 patients treated intensively, and the larger
group experienced only three major coronary events (cardiac
death or myocardial infarction) over 10 years, or 0.5% per year.73
Taken together, these findings provide evidence that lipid-lowering
therapy by statin may have a beneficial effect on plaque volume and
composition, by reducing lipid-rich core and local inflammation as
assessed by non-invasive MRI. These in vivo human studies provide
the evidence for previous observations based on histological
finding on experimental models of atherosclerosis.
Open issues
Despite rapid improvements of non-invasive imaging techniques
such as MRI for the in vivo evaluation of atherothrombosis, their
application at the clinical level is still hampered by opened issues
that require further intensive research (Table 1). For instance,
Figure 10 Matched magnetic resonance images of the right
carotid bifurcation (upper panels) and the descending aorta
(lower panels) in a hypercholesterolaemic patient at baseline
and after 24 months of simvastatin therapy. A regression of the
plaque (indicated by arrows) with small enlargement of the
lumen is evident.37,69,71 JV, jugular vein.
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studies are needed to elucidate the inter- and intra-individual varia-
bility in the distribution of atherosclerotic plaques, and the ability of
non-coronary atherosclerotic plaques imaging to predict cardio-
vascular events. In fact, most of the data presently available have
been obtained in angiographic or autopsy studies. The availability
of robust non-invasive techniques to image atherosclerotic vessels
will now allow comprehensive studies of atherosclerosis distribution
and the correlation between plaque burden and cardiac, cerebrovas-
cular, and peripheral vascular events, respectively. In addition, we are
still missing adequate data on the natural course of atherosclerosis.
Progression of atherothrombosis is most likely characterized by
non-linear growth. At present, the mechanisms of progression
remain very speculative. The discussion between balanced infiltra-
tion of lipids and inflammatory cells into the intima and media,
and healed plaque disruption remain the more accredited.
In addition, at present, it is still unknown whether spontaneous
regression of atherosclerotic lesions is also possible in adults and/
or in late stages of the disease process. In fact, in young men,
regression of early atherosclerotic lesions (such as fatty streaks)
appears to be possible. An additional crucial issue is whether the
detection of high-risk plaques will enable the prediction of cardio-
vascular events.
Despite very rapid technical evolution of all non-invasive imaging
modalities, their application in the coronary circulation remains
limited and mainly hampered by the spatial and temporal resolution.
Actual limitation and future
developments of magnetic
resonance imaging
The actual limitations of non-invasive imaging of coronary athero-
sclerosis by MRI are mainly due to technical limitation limiting tem-
poral resolution and hampering therefore its application in rapid
moving vessels such as the coronaries. Methodological limitations
derived from the lack of generally accepted protocols with standar-
dized sequences for multicontrast imaging limit its application to
hospital with MRI physicists able to modify these imaging par-
ameters. In addition, a validated automated operator-independent
software for quantitative assessment of plaque dimension and
composition is still missing. Finally, the high costs associated with
this technique will limit the use of MRI for screening purposes.
Despite these limitations, carotid MRI based on the burgeoning
data from prospective studies has placed this technique at the pre-
cipice of translation from the established imaging tool dedicated to
research purposes only to clinical practice.74
Conclusion
The assessment of atherosclerotic burden by imaging techniques
appears an essential tool for the identification of high-risk
plaques and the risk stratification of the individual patients. The
identification of asymptomatic individuals at risk for near-term
atherosclerotic events to ensure optimal preventive treatment
remains a challenging goal. The BioImage Study11, as part of the
High-risk Plaque (HRP) initiative, is a joint research and develop-
ment effort whose ultimate objective is to determine cost-effective
treatment strategies for individuals at intermediate or high cardio-
vascular risk and is aiming to evaluate the role of imaging in the
assessment of individual cardiovascular risk.75 Although not yet
available for routine use, in vivo, high-resolution, multicontrast
MRI remains the most promising method of non-invasively
imaging plaques and characterizing the main plaque components.
Intraplaque haemorrhage and the lipid-rich necrotic core are the
best indicators of lesion severity currently visualized by high-
resolution MRI. However, MRI methods capable of imaging other
important aspects of atherosclerotic disease in vivo, including
inflammation, neovascularization, and mechanical forces, are emer-
ging and may aid in advancing our understanding of the athero-
thrombotic disease.74,75
Non-invasive MRI also allows serial evaluation of the pro-
gression and regression of atherosclerosis over time. Therefore,
this technology is particular appealing to test the effects of novel
anti-atherosclerotic drugs using plaque morphology as a surrogate
endpoint before investing in hard endpoint trials.
Magnetic resonance imaging technology is evolving rapidly and
will open up new areas for the diagnosis, prevention, and treat-
ment of atherosclerosis in all arterial locations.
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